Lucas Arruda
Chief Scientific Officer CuraCell Holding AB
Dr. Lucas Arruda is the Chief Scientific Officer at CuraCell, where he leads the development of CytoPLY and CC 38—an advanced platform and clinical-stage TIL product designed to treat late-stage, immunologically cold solid tumors. Under his scientific leadership, CuraCell has presented promising clinical data from named-patient programs at both AACR and ISCT, underscoring the therapeutic potential of TILs in patients unresponsive to conventional therapies.
Seminars
As TIL therapies move beyond melanoma into more complex tumor types, new biological and manufacturing challenges emerge. This session explores the interplay between tumor biology, starting material quality, and therapeutic end-points, highlighting strategies to enhance efficacy across diverse indications.
